Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333652 · ClinicalTrials.gov registry record · Phase 2
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
A Phase 2 study of Preeclampsia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06333652 is a Phase 2 study of Preeclampsia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 14 participants, below the 1,282-participant average among 39 other Preeclampsia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06333652, a Phase 2 study of Preeclampsia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Conditions Studied
Interventions
- DRUG Ravulizumab
Study Locations (1)
Minnesota
- Mayo Clinic Minnesota - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06333652
The ClinicalTrials.gov registry entry for NCT06333652 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,282-participant average among 39 other Preeclampsia trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Preeclampsia appearing as the primary indexed condition, and to 1 intervention - of which Ravulizumab is the first listed.
NCT06333652 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT06333652 about?
NCT06333652 is a clinical study titled "Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders". The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
What is the current status of trial NCT06333652?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-03-01. Estimated completion is 2028-12-31.
What conditions does trial NCT06333652 study?
This clinical trial studies the following conditions: Preeclampsia.
What interventions are being tested in trial NCT06333652?
The interventions under investigation include: Ravulizumab (DRUG).
Who is sponsoring clinical trial NCT06333652?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333652 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preeclampsia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
RECRUITING · Phase 2
-
Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial
RECRUITING · NA
-
Daily Aspirin Treatment After Preeclampsia
RECRUITING · Early Phase 1
-
Optimizing Cardiovascular Preventive Care for Women Following Hypertensive Disorders of Pregnancy
RECRUITING · NA
-
Exosome Cargo From Preeclampsia Patients
RECRUITING
-
Prenatal Aspirin and Postpartum Vascular Function
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.